Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Guggenheim's Rating of Revance Therapeutics on 11/16/2018

On November 16, 2018, Guggenheim updated its outlook on Revance Therapeutics (NASDAQ:RVNC) with the action "Upgrade", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Guggenheim

DateCompanyAction
10/26/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Reiterated Rating
10/26/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Reiterated Rating
10/26/2026
LGN stock logo
LGN
LGN
Reiterated Rating
10/26/2026
NetApp, Inc. stock logo
NTAP
NetApp
Initiated Coverage
10/26/2026
Nutanix stock logo
NTNX
Nutanix
Initiated Coverage
10/23/2026
Paylocity Holding Corporation stock logo
PCTY
Paylocity
Boost Price Target
More Ratings From Guggenheim